BRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada

Reuters12-17

BRIEF-Knight <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada

Dec 16 (Reuters) - Knight Therapeutics Inc GUD.TO:

KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG SUBMISSION FOR QELBREE® (VILOXAZINE) IN CANADA

Source text: ID:nGNX2J7l3P

Further company coverage: GUD.TO

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492623952?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492623952","market":"us","top_or_hot":-1,"title":"BRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Knight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada</title></head><body><p><span>Dec 16 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/KHTRF\">Knight Therapeutics Inc</a> <span>GUD.TO</span>:</p><ul><li><p>KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG SUBMISSION FOR QELBREE® (VILOXAZINE) IN CANADA</p></li></ul><p>Source text: <span>ID:nGNX2J7l3P</span></p><p>Further company coverage: <span>GUD.TO</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 05:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH1EP:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In CanadaDec 16 (Reuters) - Knight Therapeutics Inc GUD.TO:KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH1EP:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH1EP:1","article_id":"2492623952","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492623952","pubTimestamp":1734385316,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In CanadaDec 16 (Reuters) - Knight Therapeutics Inc GUD.TO:KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG S","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals","BK4007":"制药"},"translate_title":"BRIEF-Knight Therapeutics宣布在加拿大提交Qelbree（维洛沙嗪）新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":0.9},"content_text":"BRIEF-Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In CanadaDec 16 (Reuters) - Knight Therapeutics Inc GUD.TO:KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG SUBMISSION FOR QELBREE® (VILOXAZINE) IN CANADASource text: ID:nGNX2J7l3PFurther company coverage: GUD.TO ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492623952"}